-
公开(公告)号：US20230117167A1
公开(公告)日：2023-04-20
申请号：US17794862
申请日：2021-01-27
发明人： Steffen Mueller , John Robert Coleman , Ying Wang , Chen Yang
IPC分类号： C07K14/005 , A61K39/215 , A61P31/14
摘要： Described herein are modified SARS-CoV-2 coronaviruses. These viruses have been recoded, for example, codon deoptimized or codon pair bias deoptimized and are useful for reducing the likelihood or severity of a SARS-CoV-2 coronavirus infection, preventing a SARS-CoV-2 coronavirus infection, eliciting and immune response, or treating a SARS-CoV-2 coronavirus infection.
-
公开(公告)号：US20210070890A1
公开(公告)日：2021-03-11
申请号：US17010084
申请日：2020-09-02
摘要： The present disclosure relates to a method for obtaining purified bacterial polysaccharides. The method comprises simultaneous removal of impurities as well as sizing of bacterial polysaccharides using an acid instead of conventional mechanical sizing methods. The method is simple, rapid and cost effective. The method results in high polysaccharide recovery and low impurity content. The purified polysaccharide obtained by the method of the present disclosure may be used for large scale production of polysaccharide-protein conjugate vaccines.
-
3.发明公开公开(公告)号：US20240350609A1
公开(公告)日：2024-10-24
申请号：US18637620
申请日：2024-04-17
发明人： Poonawalla Cyrus Soli , Dhere Rajeev Mhalasakant , Jana Swapan Kumar , Jain Shital Shantilal , Mahajan Amol Dattatraya , Paul Gourab Shankar , Malviya Hitesh Kumar , Joshi Chetan Vilas , Gautam Manish Mahesh , Kale Prathamesh Prakash , Gairola Sunil Jagdish Prasad , Mallya Asha Dinesh , Soni Dipen Jagdishbhai , Patni Sushil Vardhaman , Gavade Vinay Vijay
CPC分类号： A61K39/092 , A61K2039/55505 , A61K2039/55511 , A61K2039/575 , A61K2039/6037 , A61K2039/70
摘要： The present disclosure relates to vaccine compositions comprising pneumococcal polysaccharide-carrier protein conjugates. The present disclosure particularly relates to improved, stable, immunogenic multivalent Streptococcus pneumoniae polysaccharide-protein conjugate vaccine compositions having at least three distinct carrier proteins, preparing the vaccine compositions and methods for prevention and/or treatment of subjects with Streptococcus pneumoniae. These multivalent pneumococcal compositions will overcome carrier induced epitopic suppression, provide enhanced immune response for new serotypes (as compared to existing approved vaccines) and also help address the emergence of non-vaccine serotypes.
-
公开(公告)号：US20240299533A1
公开(公告)日：2024-09-12
申请号：US18574973
申请日：2022-06-30
发明人： Steffen Mueller , John Robert Coleman , Ying Wang , Chen Yang , Yutong Song
IPC分类号： A61K39/215 , A61K9/00 , A61K39/00 , A61P31/14 , C07K14/005 , C12N7/00
CPC分类号： A61K39/215 , A61K9/0043 , A61P31/14 , C07K14/005 , C12N7/00 , A61K2039/5254 , A61K2039/543 , A61K2039/545 , C12N2770/20021 , C12N2770/20022 , C12N2770/20034
摘要： Described herein are modified SARS-CoV-2 variants. These viruses have been recoded, for example, codon deoptimized or codon pair bias deoptimized and are useful for reducing the likelihood or severity of a SARS-CoV-2 variant infection, preventing a SARS-CoV-2 variant infection, eliciting and immune response, or treating a SARS-CoV-2 variant infection.
-
5.发明公开公开(公告)号：US20240026405A1
公开(公告)日：2024-01-25
申请号：US18212815
申请日：2023-06-22
IPC分类号： C12P19/04 , A61K39/095
CPC分类号： C12P19/04 , A61K39/095 , A61K2039/6037
摘要： The present invention relates to an improved process for purification of bacterial capsular polysaccharides, more specifically capsular polysaccharides of gram negative bacteria. The process comprises of concentration and diafiltration of harvest, treatment with anionic detergent and strong alkali followed by centrifugation, diafiltration and cationic detergent based precipitation of bacterial polysaccharides. The process results in significant reduction of endotoxin, protein and nucleic acid impurities thereby providing higher recovery of capsular polysaccharide with the desired O-acetyl levels. Said process is scalable, non-enzymatic, and employs fewer purification steps.
-
公开(公告)号：US11660333B2
公开(公告)日：2023-05-30
申请号：US16756227
申请日：2018-10-10
发明人： Rajeev Mhalasakant Dhere , Leena Ravindra Yeolekar , Vinit Kumar , Rohit Bapurav Sonar , Sandeep Dinkar Baraskar , Rajeev Mehla , Shashikant Janardan Ghodekar , Cyrus Soli Poonawalla , Adar Cyrus Poonawalla
CPC分类号： A61K39/12 , C12N7/06 , A61K2039/5254 , A61K2039/55505 , A61K2039/55561 , A61K2039/55566 , A61K2039/55572 , A61K2039/55577 , A61K2039/55583 , C12N2770/24134
摘要： Stable lyophilized immunogenic compositions include inter alia live attenuated recombinant flaviviruses, more preferably live attenuated recombinant dengue viruses, at least one carbohydrate, at least one amino acid and is particularly amenable to rapid freeze-drying treatments wherein, the composition preserves desired characteristics of a virus, including virus viability, immunogenicity and stability. The immunogenic composition is devoid of preservatives, polymers and surfactants. The methods for manufacturing the stable lyophilized immunogenic compositions are also provided.
-
公开(公告)号：US10233231B2
公开(公告)日：2019-03-19
申请号：US15203035
申请日：2016-07-06
发明人： Dhere Rajeev Mhalasakant , Pisal Sambhaji Shankar , Peddi Reddy Srinivas Reddy , Singh Digamber Chahar , Pardeep Gupta
IPC分类号： C07K16/00 , C07K16/10 , A61K39/395 , C07K1/22
摘要： This invention provides an improved process for manufacturing a Rabies monoclonal antibody (HuMab 17C7) that results in low osmolality, minimum secondary metabolites like ammonia and lactate, enhanced cell growth and productivity, minimum aggregation or degradation of monoclonal antibody during purification, thereby improving potency of monoclonal antibody (HuMab 17C7) as compared to human rabies immunoglobulin (hRIG).
-
公开(公告)号：US20170088873A1
公开(公告)日：2017-03-30
申请号：US15203035
申请日：2016-07-06
发明人： DHERE RAJEEV MHALASAKANT , PISAL SAMBHAJI SHANKAR , PEDDI REDDY SRINIVAS REDDY , SINGH DIGAMBER CHAHAR , PARDEEP GUPTA
CPC分类号： C07K16/10 , A61K39/39591 , C07K1/22 , C07K2317/21 , C07K2317/76
摘要： This invention provides an improved process for manufacturing a Rabies monoclonal antibody (HuMab 17C7) that results in low osmolality, minimum secondary metabolites like ammonia and lactate, enhanced cell growth and productivity, minimum aggregation or degradation of monoclonal antibody during purification, thereby improving potency of monoclonal antibody (HuMab 17C7) as compared to human rabies immunoglobulin (hRIG).
-
公开(公告)号：US20230183765A1
公开(公告)日：2023-06-15
申请号：US17924405
申请日：2021-05-13
摘要： The present disclosure relates to alternative, cost effective, rapid and simple methods for bacterial capsular polysaccharide (CPS) manufacturing resulting in 1) simultaneous sizing and purification of CPS 2) high CPS yield, 3) improved CPS purity and removal of protein and nucleic acid contaminants, 4) CPS with preserved epitopic conformation and 5) stable and immunogenic polysaccharide-protein conjugate vaccines comprising of said size reduced and purified CPS The method particularly comprises subjecting crude/native bacterial polysaccharide to an oxidizing agent to obtain high purity, high yield and structurally intact CPS having optimal molecular size and other desirable CPS attributes. The method is amenable for commercial scale manufacturing of polysaccharide-protein conjugate vaccines.
-
10.发明公开公开(公告)号：US20230165950A1
公开(公告)日：2023-06-01
申请号：US17814988
申请日：2022-07-26
发明人： Rémi PALMANTIER , Yolande MISSERI , Caroline DIVEU-SADER , Sunil GAIROLA , Manish GAUTAM , Harish RAO , Umesh SHALIGRAM
IPC分类号： A61K39/02 , A61K9/00 , A61K39/05 , A61K39/08 , A61K39/102 , A61K39/13 , A61K39/29 , A61K39/39 , A61K39/00
CPC分类号： A61K39/099 , A61K9/0019 , A61K39/05 , A61K39/08 , A61K39/102 , A61K39/13 , A61K39/292 , A61K39/39 , C12Y406/01001 , A61K39/0018 , A61K2039/55505 , A61K2039/55561 , A61K2039/55572 , A61K2039/55594 , C12N2730/10134 , C12N2770/32634 , A61K2039/10
摘要： The invention relates to the use of a polypeptide derived from the adenylate cyclase of a Bordetella sp. (CyaA-derived polypeptide) by deletion of a segment of at least 93 amino acid residues, in particular a polypeptide derived from CyaA of Bordetella pertussis, as an immunomodifying antigen of the TH1/TH17-oriented immune response in an immunogenic composition. The invention relates to a vaccine candidate comprising such CyaA-derived polypeptide, either in an acellular immunogenic composition for active immunization against a condition causally related to the infection of a host by Bordetella sp. or in a combination composition encompassing said acellular immunogenic composition.
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.023 秒)
